First PREMIER Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

First PREMIER Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-122	Closed	-$11K	–	408
2024 Q1	$11K	Buy	+122	New	+$10.9K	﹤0.01%	316

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

First PREMIER Bank's BMRN Position: Q2 2024 in Review

First PREMIER Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 122 shares — an estimated $11K sold.

First PREMIER Bank first reported a position in BMRN in Q1 2024 and held it in 1 quarter. The position peaked at $11K in Q1 2024. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

First PREMIER Bank reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
First PREMIER Bank sold 122 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $11K.
First PREMIER Bank first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 1 quarter.
First PREMIER Bank's BioMarin Pharmaceuticals position peaked at $11K in Q1 2024.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on First PREMIER Bank's 13F filing for Q2 2024, filed 17 Jul 2024.